



Ventripoint Issues Option Grants and Exercises

Toronto, Ontario, January 27, 2021 – Ventripoint Diagnostics Ltd. (“**Ventripoint**” or the “**Corporation**”, TSXV:VPT & OTC:VPTDF) announces that on January 19, 2021 the Board of Directors approved the granting of 825,000 options to consultants at exercise prices from \$0.135 to \$0.20 for a term of 1 year, with vesting over 4 months. The Corporation is also announcing that 900,000 options with an exercise price of \$0.10 have been exercised in the January 2021. The Corporation now has 1,567,435 options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting on December 14, 2020.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Mr. Peter Weichler, Director
Email: peter@weichler.ca

Or

Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.